Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.67 | N/A | +67.08% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.67 | N/A | +67.08% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized their focus on upcoming projects.
Management expressed satisfaction with the EPS results despite not providing revenue figures.
They highlighted ongoing projects and potential future developments.
Ligand Pharmaceuticals reported a positive surprise in EPS, which indicates better-than-expected profitability. However, the stock saw a slight decline of 0.19%, likely due to the lack of revenue information and guidance. Investors may be cautious as they await more detailed financial insights in future reports.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CBOE GLOBAL MKTS INC
Aug 4, 2017